ArticleBMC nephrology2025
Posttransplant diabetes mellitus and long-term outcomes after kidney transplantation in a steroid avoidance regimen: a cohort study.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPosttransplant diabetes mellitus (PTDM) is associated with reduced patient survival and death-censored graft survival and has been linked to steroid use and obesity. Steroid avoidance regimens have been associated with a reduction in PTDM without impacting patient or graft survival followed up for 5 years following kidney transplantation; however, acute rejection remains a concern. The primary objective of this study was to assess death-censored graft and patient survival outcomes and report on PTDM onset in patients receiving steroid-avoidance immunosuppressant regimens over 11 years.
methodsThis was a retrospective cohort study from a single center in the UK that included first kidney transplants between 2010 and 2021. Logistic regression models and Cox proportional hazards models were used to investigate associations between survival and PTDM. A P value < 0.05 was considered to indicate statistical significance.
resultsThere was no difference in patient or graft survival among those with PTDM, preexisting diabetes or no diabetes. 16% (n = 55) developed PTDM over a median follow-up of 7.1 years (range: 0.9–13.8 years). After adjusting for confounding factors, the odds of PTDM diagnosis were associated with increasing BMI (odds ratio (OR): 1.01; 95% CI: 1.03–1.18), and white ethnicity was associated with reduced odds of PTDM (OR: 0.45; 95% CI: 0.23–0.90).
conclusionsOur findings support lower PTDM rates and safe longer-term outcomes following a steroid-free regimen. Timely weight management interventions before transplantation, particularly in high-risk groups, may reduce PTDM in this population. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.